HC Wainwright Reiterates “Buy” Rating for Jaguar Health (JAGX)

HC Wainwright restated their buy rating on shares of Jaguar Health (NASDAQ:JAGX) in a research report report published on Monday, Zacks.com reports.

Separately, ValuEngine downgraded Jaguar Health from a buy rating to a hold rating in a research report on Thursday, January 24th.

JAGX stock opened at $0.28 on Monday. Jaguar Health has a twelve month low of $0.12 and a twelve month high of $3.20.

About Jaguar Health

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

See Also: What is a Futures Contract?

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.